AbstractBy using a limited-proteolysis strategy that employs a large amount of trypsin to generate peptides directly from native proteins, we found that ligand-induced protein local stability shifts can be sensitively detected on a proteome-wide scale. This enabled us to develop the peptide-centric local stability assay, a modification-free approach that achieves unprecedented sensitivity in proteome-wide target identification and binding-region determination. We demonstrate the broad applications of the peptide-centric local stability assay by investigating interactions across various biological contexts.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Learn more
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: Establishment of PELSA.Fig. 2: Comparing target identification performance of PELSA with existing modification-free methods.
Data availability
The raw mass spectrometry proteomics data, protein identification and quantification results have been deposited with the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD034606. The source data associated with Supplementary Figs. 1–21 are available via Figshare at https://doi.org/10.6084/m9.figshare.26886625 (ref. 28). The source data include all primary datasets and referenced datasets. The Supplementary Tables referenced in the Supplementary Notes are published alongside this paper. A step-by-step PELSA protocol has been deposited via protocols.io with the link https://doi.org/10.17504/protocols.io.q26g717x1gwz/v2 (ref. 29). Protein structures are download from PDB (https://www.rcsb.org/) with accession codes: 1FAP (FKBP1A-mTOR), 1U72 (DHFR), 5EHR (PTPN11), 2D8Y (LIMA1), 2PSN (ENO1), 4DMB (HDDC2), AF-Q9H2U2-F1-mod (PPA2), 1WAO (PPP5C), 5LN3 (human 26S Proteasome), 1BOZ and 4EJ1 (DHFR-folate), 1P4R (ATIC), 1RBY (GART) and 6KQY (LARS1). The reviewed human fasta database was downloaded from UniProt in June 2018 (https://www.uniprot.org/uniprotkb). Source data are provided with this paper.
Code availability
The code of PELSA data processing pipeline is available via GitHub at https://github.com/DICP-1809/PELSA-Decipher.
ReferencesKaur, U. et al. Proteome-wide structural biology: an emerging field for the structural analysis of proteins on the proteomic scale. J. Proteome Res. 17, 3614–3627 (2018).Article
CAS
PubMed
PubMed Central
Google Scholar
Lyu, J., Wang, K. & Ye, M. Modification-free approaches to screen drug targets at proteome level. Trends Anal. Chem. 124, 115574 (2020).Article
CAS
Google Scholar
Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013).Article
PubMed
Google Scholar
Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 55 (2014).Article
CAS
Google Scholar
Lomenick, B. et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl Acad. Sci. USA 106, 21984–21989 (2009).Article
CAS
PubMed
PubMed Central
Google Scholar
Schopper, S. et al. Measuring protein structural changes on a proteome-wide scale using limited proteolysis-coupled mass spectrometry. Nat. Protoc. 12, 2391–2410 (2017).Article
CAS
PubMed
Google Scholar
Piazza, I. et al. A map of protein-metabolite interactions reveals principles of chemical communication. Cell 172, 358–372.e323 (2018).Article
CAS
PubMed
Google Scholar
Feng, Y. H. et al. Global analysis of protein structural changes in complex proteomes. Nat. Biotechnol. 32, 1036–1044 (2014).Article
CAS
PubMed
Google Scholar
Piazza, I. et al. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes. Nat. Commun. 11, 4200 (2020).Article
PubMed
PubMed Central
Google Scholar
Tian, Y. et al. Chemoproteomic mapping of the glycolytic targetome in cancer cells. Nat. Chem. Biol. 19, 1480–1491 (2023).Article
CAS
PubMed
Google Scholar
Ruan, C. et al. Proteome-wide deconvolution of drug targets and binding sites by lysine reactivity profiling. Anal. Chem. 94, 3352–3359 (2022).Article
CAS
PubMed
Google Scholar
Tan, S. & Richmond, T. J. DNA binding-induced conformational change of the yeast transcriptional activator PRTF. Cell 62, 367–377 (1990).Article
CAS
PubMed
Google Scholar
Fontana, A. et al. Probing protein structure by limited proteolysis. Acta Biochim. Pol. 51, 299–321 (2004).Article
CAS
PubMed
Google Scholar
Scaltriti, M. et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803–814 (2009).Article
CAS
PubMed
Google Scholar
Li, J., Kim, S. G. & Blenis, J. Rapamycin: one drug, many effects. Cell Metab. 19, 373–379 (2014).Article
CAS
PubMed
PubMed Central
Google Scholar
März, A. M., Fabian, A.-K., Kozany, C., Bracher, A. & Hausch, F. Large FK506-binding proteins shape the pharmacology of rapamycin. Mol. Cell. Biol. 33, 1357–1367 (2013).Article
PubMed
PubMed Central
Google Scholar
Ball, K. A. et al. An isothermal shift assay for proteome scale drug-target identification. Commun. Biol. 3, 75 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Zinn, N. et al. Improved proteomics-based drug mechanism-of-action studies using 16-plex isobaric mass tags. J. Proteome Res. 20, 1792–1801 (2021).Article
CAS
PubMed
Google Scholar
Ruan, C. et al. Matrix thermal shift assay for fast construction of multidimensional ligand–target space. Anal. Chem. 94, 6482–6490 (2022).Article
CAS
PubMed
Google Scholar
Nam, N. H. et al. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain. Bioorg. Med. Chem. 12, 779–787 (2004).Article
CAS
PubMed
Google Scholar
Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359–362 (2009).Article
CAS
PubMed
Google Scholar
Liao, R., Gao, Y., Chen, M., Li, L. & Hu, X. A ubiquitous but overlooked side reaction in dimethyl labeling of peptides. Anal. Chem. 90, 13533–13540 (2018).Article
CAS
PubMed
Google Scholar
Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 11, 2301–2319 (2016).Article
CAS
PubMed
Google Scholar
Losman, J. A., Koivunen, P. & Kaelin, W. G. Jr. 2-Oxoglutarate-dependent dioxygenases in cancer. Nat. Rev. Cancer 20, 710–726 (2020).Article
CAS
PubMed
Google Scholar
Waldron, T. T. & Murphy, K. P. Stabilization of proteins by ligand binding: application to drug screening and determination of unfolding energetics. Biochemistry 42, 5058–5064 (2003).Article
CAS
PubMed
Google Scholar
Cimmperman, P. et al. A quantitative model of thermal stabilization and destabilization of proteins by ligands. Biophys. J. 95, 3222–3231 (2008).Article
CAS
PubMed
PubMed Central
Google Scholar
Blum, M. et al. The InterPro protein families and domains database: 20 years on. Nucleic Acids Res. 49, D344–D354 (2021).Article
CAS
PubMed
Google Scholar
Li, K. Source data for PELSA SI figures. Figshare https://doi.org/10.6084/m9.figshare.26886625 (2024).Li, K. & Ye, M. PELSA protocol v.2. Protocols.io https://doi.org/10.17504/protocols.io.q26g717x1gwz/v2 (2024).Download referencesAcknowledgementsWe thank M. Savitski from the European Molecular Biology Laboratory for the fruitful discussion, for revising this manuscript and the point-by-point replies during the revision process. This work was supported, in part, by funds from the National Key Research and Development Program of China (grant no. 2021YFA1302601 to M.Y.), the National Natural Science Foundation of China (grant nos. 92153302, 22437007 to M.Y., 22137002 to K.W., 92253303 to C.L., 22204033 to Y.L.), Dalian Science and Technology Innovation Fund (grant no. 2023JJ11CG006 to M.Y.), the innovation program of science and research from the DICP, CAS (grant nos. DICP I202109, DICP I202139 to M.Y.), the project of National Multidisciplinary Innovation Team of Traditional Chinese Medicine from National Administration of Traditional Chinese Medicine (grant no. ZYYCXTD-202004 to C.L.), the Youth Innovation Promotion Association of CAS (grant no. 2022279 to S.C.). Author informationAuthor notesKejia LiPresent address: Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, GermanyJiawen LyuPresent address: Department of Oncology-Pathology, Karolinska Institute, Stockholm, SwedenAuthors and AffiliationsState Key Laboratory of Medical Proteomics, CAS Key Laboratory of Separation Sciences for Analytical Chemistry, National Chromatographic R&A Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Dalian, ChinaKejia Li, Keyun Wang, Yan Wang, Lianji Xue, Yuying Ye, Zheng Fang, Jiawen Lyu, Haiyang Zhu, Yanan Li, Ting Yu, Xiaolei Zhang, Chengfei Ruan, Jiahua Zhou, Qi Wang & Mingliang YeUniversity of Chinese Academy of Sciences, Beijing, ChinaKejia Li, Lianji Xue, Yuying Ye, Zheng Fang, Jiawen Lyu, Haiyang Zhu, Ting Yu, Chengfei Ruan, Jiahua Zhou, Qi Wang & Mingliang YeDrug Discovery and Design Center, the Center for Chemical Biology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaShijie Chen, Feng Yang, Siqi Guo & Cheng LuoMOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, ChinaMingming DongSchool of Pharmacy, Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, ChinaCheng LuoAuthorsKejia LiView author publicationsYou can also search for this author in
PubMed Google ScholarShijie ChenView author publicationsYou can also search for this author in
PubMed Google ScholarKeyun WangView author publicationsYou can also search for this author in
PubMed Google ScholarYan WangView author publicationsYou can also search for this author in
PubMed Google ScholarLianji XueView author publicationsYou can also search for this author in
PubMed Google ScholarYuying YeView author publicationsYou can also search for this author in
PubMed Google ScholarZheng FangView author publicationsYou can also search for this author in
PubMed Google ScholarJiawen LyuView author publicationsYou can also search for this author in
PubMed Google ScholarHaiyang ZhuView author publicationsYou can also search for this author in
PubMed Google ScholarYanan LiView author publicationsYou can also search for this author in
PubMed Google ScholarTing YuView author publicationsYou can also search for this author in
PubMed Google ScholarFeng YangView author publicationsYou can also search for this author in
PubMed Google ScholarXiaolei ZhangView author publicationsYou can also search for this author in
PubMed Google ScholarSiqi GuoView author publicationsYou can also search for this author in
PubMed Google ScholarChengfei RuanView author publicationsYou can also search for this author in
PubMed Google ScholarJiahua ZhouView author publicationsYou can also search for this author in
PubMed Google ScholarQi WangView author publicationsYou can also search for this author in
PubMed Google ScholarMingming DongView author publicationsYou can also search for this author in
PubMed Google ScholarCheng LuoView author publicationsYou can also search for this author in
PubMed Google ScholarMingliang YeView author publicationsYou can also search for this author in
PubMed Google ScholarContributionsM.Y., K.L. and K.W. conceived and designed the project. K.L. developed the method, carried out the experiments and analyzed the results under the supervision of M.Y. S.C., F.Y. and S.G. measured the binding affinities of purified HSP90AA1 to HSP90 inhibitors and validated the off-targets identified for HSP90 inhibitors and R2HG under the supervision of C.L. K.W. advised on the experimental design. Y.W. set up the MS analysis methods, discussed the experiment results and edited the manuscript. L.X. performed the dose-dependent rapamycin/geldanamycin/tanespimycin/ganetespib PELSA experiments and tested different enzyme quantities. Y.Y. performed the fumarate-PELSA, succinate-PELSA, folate-TPP and leucine-TPP experiments. Z.F. gave help with data processing. J.L. helped in the experiment investigating PTM’s readers. H.Z. helped in data processing in the Zn2+ experiment. Y.L. helped to correct the manuscript. T.Y. advised on investigating the leucine-binding proteins. J.Z. helped in calculating the Euclidean distances between peptides and ligands. X.Z., C.R. and Q.W. gave scientific advice. M.D. discussed the results and revised the manuscript. K.L. and M.Y. wrote the paper with input from other authors.Corresponding authorsCorrespondence to
Cheng Luo or Mingliang Ye.Ethics declarations
Competing interests
A patent application related to this work has been filed by Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Peer review
Peer review information
Nature Methods thanks Marcus Bantscheff and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Allison Doerr, in collaboration with the Nature Methods team.
Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Extended dataExtended Data Fig. 1 PELSA determines the binding regions and affinities of rapamycin with FKBP family proteins.a, Local stability profiles of FKBP family proteins under 2 µM rapamycin treatment. Only peptides from FKBP domains display altered abundance. b, Dose-response curves of FKBP1A peptides (left) and FKBP1A protein (right) measured by PELSA in HeLa cell lysates toward rapamycin. The protein-level dose-response curve is generated by fitting the averaged fold change values of all qualified peptides across each rapamycin concentration. c, Binding affinities between rapamycin and FKBP1A peptides measured by LiP-Quant. DRC refers to the Pearson correlation coefficient of the dose-response curve; LiP-Quant score indicates the likelihood of being a genuine drug-binding protein. Data are extracted from the literature9. d, Protein-level dose-response curves of FKBP family proteins measured by PELSA.Source dataExtended Data Fig. 2 The staurosporine targets determined in PELSA analyses and thermal shift-based studies.a, Overlap analysis of staurosporine targets identified by PELSA in HeLa and K562 cell lysates. Kinases are considered true positive targets, while the non-kinase targets are listed based on their identification in HeLa and K562 cell lysates. b, Comparing the number of staurosporine targets determined in PELSA and thermal shift-based studies in K562 cell lysates. The percentage of kinase targets among all the determined staurosporine targets (that is, true positive rate, TPR) is indicated for each study.Source dataSupplementary informationSupplementary InformationSupplementary Notes 1–18 and Figs. 1–21.Reporting SummarySupplementary Table 1–8Supplementary Tables 1–8 related to the Supplementary Notes.Source dataSource Data Fig. 1Statistical source data.Source Data Fig. 2Statistical source data.Source Data Extended Data Fig. 1Statistical source data.Source Data Extended Data Fig. 2Statistical source data.Rights and permissionsSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.Reprints and permissionsAbout this articleCite this articleLi, K., Chen, S., Wang, K. et al. A peptide-centric local stability assay enables proteome-scale identification of the protein targets and binding regions of diverse ligands.
Nat Methods (2024). https://doi.org/10.1038/s41592-024-02553-7Download citationReceived: 19 October 2023Accepted: 30 October 2024Published: 10 December 2024DOI: https://doi.org/10.1038/s41592-024-02553-7Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative